Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 January 2011
Bipolar disorder, psychosis and schizophrenia in children and young people (QS102)Product type:Quality standardPublished: 15 October 2015
Coexisting severe mental illness and substance misuse (QS188)Product type:Quality standardPublished: 20 August 2019
Coexisting severe mental illness and substance misuse: community health and social care services (NG58)Product type:GuidanceProgramme:NICE guidelinePublished: 30 November 2016
Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings (CG120)Product type:GuidanceProgramme:Clinical guidelinePublished: 23 March 2011
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment (HTE17)Product type:GuidanceProgramme:Health technology evaluationPublished: 25 March 2024
Guidance on the use of electroconvulsive therapy (TA59)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 October 2009Published: 26 April 2003
Iclepertin for treating cognitive impairment associated with schizophrenia ID6483Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication (HTE10)Product type:GuidanceProgramme:Health technology evaluationPublished: 26 September 2023
Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 May 2013
Psychosis and schizophrenia in adults: prevention and management (CG178)Product type:GuidanceProgramme:Clinical guidelineLast updated: 1 March 2014Published: 12 February 2014
Psychosis and schizophrenia in children and young people: recognition and management (CG155)Product type:GuidanceProgramme:Clinical guidelineLast updated: 26 October 2016Published: 23 January 2013
Rehabilitation for adults with complex psychosis (NG181)Product type:GuidanceProgramme:NICE guidelinePublished: 19 August 2020
Schizophrenia: lurasidone (ESNM48)Product type:AdviceProgramme:Evidence summaryPublished: 23 September 2014
Schizophrenia: omega-3 fatty acid medicines (ESUOM19)Product type:AdviceProgramme:Evidence summaryPublished: 24 September 2013
Structural neuroimaging in first-episode psychosis (TA136)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 February 2008
Transcranial magnetic stimulation for auditory hallucinations (IPG680)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 September 2020
Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTE15)Product type:GuidanceProgramme:Health technology evaluationPublished: 15 November 2023